Amit Sachdev, EVP, Chief Patient Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 36,955 shares at $248.73 ($9.0M) on 2020-02-11, disclosed to the SEC on 2020-02-12.
Seasonal sale ($9.0M) by EVP, Chief Patient Officer — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $240.95 | 12,215 | $2.9M | 32.6% |
| 2 | $243.53 | 1,000 | $244K | 2.7% |
| 3 | $245.05 | 3,426 | $840K | 9.3% |
| 4 | $245.05 | 3,426 | $840K | 9.3% |
| 5 | $245.99 | 4,320 | $1.1M | 11.8% |
| 6 | $245.99 | 4,320 |
| $1.1M |
| 11.8% |
| 7 | $246.88 | 1,821 | $450K | 5.0% |
| 8 | $246.88 | 1,821 | $450K | 5.0% |
| 9 | $247.98 | 2,103 | $522K | 5.8% |
| 10 | $247.98 | 2,103 | $522K | 5.8% |
| 11 | $248.73 | 400 | $99K | 1.1% |
| Total | $244.43 avg | 36,955 | $9.0M | 100% |
| Filing → |
| VRTX | SELL | 2024-05-17 | $14K | — | Filing → |
| VRTX | SELL | 2024-02-27 | $2.6M | — | Filing → |
| VRTX | SELL | 2024-02-23 | $2.7M | — | Filing → |